aluates Reports

$ 0.0

Automative

Global Oligonucleotide Therapeutics Market Research Report 2026

Published Date: 2026-02-27

Report Code: QYRE-Auto-26O10944

Global Oligonucleotide Therapeutics Sales Market Report 2022

BUY CHAPTERS

Global Oligonucleotide Therapeutics Market Research Report 2026

Code: QYRE-Auto-26O10944

Report

2026-02-27

Pages:129

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Biogen

Sarepta Therapeutics

Jazz Pharmaceuticals

Ionis Pharmaceuticals

Alnylam

Nippon Shinyaku

SOBI

Novartis

BioNTech

Pfizer Inc

Moderna Therapeutics

CureVac

Regulus Therapeutics

ProQR

Secarna

Mina Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

Oligonucleotide Therapeutics Market Size

The global Oligonucleotide Therapeutics market was valued at US$ 7788 million in 2025 and is anticipated to reach US$ 10010 million by 2032, at a CAGR of 3.7% from 2026 to 2032.

Oligonucleotide Therapeutics Market

Oligonucleotide therapeutics are a class of precision medicines composed of short DNA or RNA sequences designed to specifically target and modulate the expression of genes involved in disease processes. These therapies can act by silencing, inhibiting, or correcting genetic abnormalities at the molecular level, offering a highly targeted approach to treat various conditions such as genetic disorders, cancers, and viral infections. Oligonucleotide therapeutics include antisense oligonucleotides, small interfering RNA (siRNA), and aptamers, and they represent a promising area of drug development due to their ability to address previously untreatable diseases.

Key driver of the oligonucleotide therapeutics market is the growing prevalence of genetic and rare diseases that require precise and targeted treatment options. Advances in genomics and personalized medicine have fueled interest in oligonucleotide therapies, which can directly modulate gene expression and offer solutions for conditions that were previously difficult to treat. The success of approved oligonucleotide drugs, such as antisense oligonucleotides and siRNA therapies, has increased confidence in this field, leading to more investments and research in developing novel treatments for a wide range of diseases, including cancers and neurological disorders.

One significant challenge in the oligonucleotide therapeutics market is the complexity of delivering these molecules effectively to target cells or tissues. Oligonucleotides are large, negatively charged molecules that face hurdles in stability, bioavailability, and efficient cellular uptake. Developing delivery systems that can ensure targeted and sustained delivery while minimizing immune responses or off-target effects remains a critical challenge. Additionally, the high costs associated with research, development, and manufacturing of oligonucleotide-based drugs pose financial challenges, limiting accessibility and widespread adoption, especially in resource-constrained healthcare settings.

Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023. Following Europe, North Americas is the second largest consumption place with the consumption market share of 34.9%. The global key companies of oligonucleotide therapeutics include Pfizer, Moderna Therapeutics, BioNTech, Biogen, Alnylam, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, Novartis, Sobi, Ionis Pharmaceuticals, etc. In 2023, the global top five players had a share approximately 97.87% in terms of revenue.

This report delivers a comprehensive overview of the global Oligonucleotide Therapeutics market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Oligonucleotide Therapeutics. The Oligonucleotide Therapeutics market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Oligonucleotide Therapeutics market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Oligonucleotide Therapeutics manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Oligonucleotide Therapeutics Market Report

Report Metric	Details
Report Name	Oligonucleotide Therapeutics Market
Accounted market size in 2025	US$ 7788 in million
Forecasted market size in 2032	US$ 10010 million
CAGR	3.7%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Antisense Oligonucleotides (ASO) siRNA mRNA
Segment by Application	Neuromuscular Diseases hATTR COVID-19 Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Oligonucleotide Therapeutics companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Oligonucleotide Therapeutics Market growing?

Ans: The Oligonucleotide Therapeutics Market witnessing a CAGR of 3.7% during the forecast period 2026-2032.

What is the Oligonucleotide Therapeutics Market size in 2032?

Ans: The Oligonucleotide Therapeutics Market size in 2032 will be US$ 10010 million.

What is the Oligonucleotide Therapeutics Market share by region?

Ans: Europe is the largest consumption place, with a consumption market share nearly 44.61% in 2023.

What is the market share of major companies in Oligonucleotide Therapeutics Market?

Ans: In 2023, the global top five players had a share approximately 97.87% in terms of revenue.

Who are the main players in the Oligonucleotide Therapeutics Market report?

Ans: The main players in the Oligonucleotide Therapeutics Market are Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, Nippon Shinyaku, Sobi, Novartis, BioNTech, Pfizer, Moderna Therapeutics, Jazz Pharmaceuticals, CureVac, Regulus Therapeutics, ProQR, Secarna, MiNA Therapeutics, Sylentis, Arrowhead, Silence Therapeutics, Dicerna

What are the Application segmentation covered in the Oligonucleotide Therapeutics Market report?

Ans: The Applications covered in the Oligonucleotide Therapeutics Market report are Neuromuscular Diseases, hATTR, COVID-19, Other

What are the Type segmentation covered in the Oligonucleotide Therapeutics Market report?

Ans: The Types covered in the Oligonucleotide Therapeutics Market report are Antisense Oligonucleotides (ASO), siRNA, mRNA

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Antisense Oligonucleotides (ASO)

1.2.3 siRNA

1.2.4 mRNA

1.3 Market by Application

1.3.1 Global Oligonucleotide Therapeutics Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Neuromuscular Diseases

1.3.3 hATTR

1.3.4 COVID-19

1.3.5 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Oligonucleotide Therapeutics Market Perspective (2021–2032)

2.2 Global Oligonucleotide Therapeutics Growth Trends by Region

2.2.1 Global Oligonucleotide Therapeutics Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Oligonucleotide Therapeutics Historic Market Size by Region (2021–2026)

2.2.3 Oligonucleotide Therapeutics Forecasted Market Size by Region (2027–2032)

2.3 Oligonucleotide Therapeutics Market Dynamics

2.3.1 Oligonucleotide Therapeutics Industry Trends

2.3.2 Oligonucleotide Therapeutics Market Drivers

2.3.3 Oligonucleotide Therapeutics Market Challenges

2.3.4 Oligonucleotide Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Oligonucleotide Therapeutics Players by Revenue

3.1.1 Global Top Oligonucleotide Therapeutics Players by Revenue (2021–2026)

3.1.2 Global Oligonucleotide Therapeutics Revenue Market Share by Players (2021–2026)

3.2 Global Top Oligonucleotide Therapeutics Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Oligonucleotide Therapeutics Revenue

3.4 Global Oligonucleotide Therapeutics Market Concentration Ratio

3.4.1 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Therapeutics Revenue in 2025

3.5 Global Key Players of Oligonucleotide Therapeutics Head Offices and Areas Served

3.6 Global Key Players of Oligonucleotide Therapeutics, Products and Applications

3.7 Global Key Players of Oligonucleotide Therapeutics, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Oligonucleotide Therapeutics Breakdown Data by Type

4.1 Global Oligonucleotide Therapeutics Historic Market Size by Type (2021–2026)

4.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Type (2027–2032)

5 Oligonucleotide Therapeutics Breakdown Data by Application

5.1 Global Oligonucleotide Therapeutics Historic Market Size by Application (2021–2026)

5.2 Global Oligonucleotide Therapeutics Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Oligonucleotide Therapeutics Market Size (2021–2032)

6.2 North America Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Oligonucleotide Therapeutics Market Size by Country (2021–2026)

6.4 North America Oligonucleotide Therapeutics Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Oligonucleotide Therapeutics Market Size (2021–2032)

7.2 Europe Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Oligonucleotide Therapeutics Market Size by Country (2021–2026)

7.4 Europe Oligonucleotide Therapeutics Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Oligonucleotide Therapeutics Market Size (2021–2032)

8.2 Asia-Pacific Oligonucleotide Therapeutics Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2021–2026)

8.4 Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Oligonucleotide Therapeutics Market Size (2021–2032)

9.2 Latin America Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Oligonucleotide Therapeutics Market Size by Country (2021–2026)

9.4 Latin America Oligonucleotide Therapeutics Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Oligonucleotide Therapeutics Market Size (2021–2032)

10.2 Middle East & Africa Oligonucleotide Therapeutics Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2021–2026)

10.4 Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sarepta Therapeutics

11.1.1 Sarepta Therapeutics Company Details

11.1.2 Sarepta Therapeutics Business Overview

11.1.3 Sarepta Therapeutics Oligonucleotide Therapeutics Introduction

11.1.4 Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.1.5 Sarepta Therapeutics Recent Development

11.2 Ionis Pharmaceuticals

11.2.1 Ionis Pharmaceuticals Company Details

11.2.2 Ionis Pharmaceuticals Business Overview

11.2.3 Ionis Pharmaceuticals Oligonucleotide Therapeutics Introduction

11.2.4 Ionis Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.2.5 Ionis Pharmaceuticals Recent Development

11.3 Alnylam

11.3.1 Alnylam Company Details

11.3.2 Alnylam Business Overview

11.3.3 Alnylam Oligonucleotide Therapeutics Introduction

11.3.4 Alnylam Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.3.5 Alnylam Recent Development

11.4 Biogen

11.4.1 Biogen Company Details

11.4.2 Biogen Business Overview

11.4.3 Biogen Oligonucleotide Therapeutics Introduction

11.4.4 Biogen Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.4.5 Biogen Recent Development

11.5 Nippon Shinyaku

11.5.1 Nippon Shinyaku Company Details

11.5.2 Nippon Shinyaku Business Overview

11.5.3 Nippon Shinyaku Oligonucleotide Therapeutics Introduction

11.5.4 Nippon Shinyaku Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.5.5 Nippon Shinyaku Recent Development

11.6 Sobi

11.6.1 Sobi Company Details

11.6.2 Sobi Business Overview

11.6.3 Sobi Oligonucleotide Therapeutics Introduction

11.6.4 Sobi Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.6.5 Sobi Recent Development

11.7 Novartis

11.7.1 Novartis Company Details

11.7.2 Novartis Business Overview

11.7.3 Novartis Oligonucleotide Therapeutics Introduction

11.7.4 Novartis Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.7.5 Novartis Recent Development

11.8 BioNTech

11.8.1 BioNTech Company Details

11.8.2 BioNTech Business Overview

11.8.3 BioNTech Oligonucleotide Therapeutics Introduction

11.8.4 BioNTech Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.8.5 BioNTech Recent Development

11.9 Pfizer

11.9.1 Pfizer Company Details

11.9.2 Pfizer Business Overview

11.9.3 Pfizer Oligonucleotide Therapeutics Introduction

11.9.4 Pfizer Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.9.5 Pfizer Recent Development

11.10 Moderna Therapeutics

11.10.1 Moderna Therapeutics Company Details

11.10.2 Moderna Therapeutics Business Overview

11.10.3 Moderna Therapeutics Oligonucleotide Therapeutics Introduction

11.10.4 Moderna Therapeutics Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.10.5 Moderna Therapeutics Recent Development

11.11 Jazz Pharmaceuticals

11.11.1 Jazz Pharmaceuticals Company Details

11.11.2 Jazz Pharmaceuticals Business Overview

11.11.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Introduction

11.11.4 Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.11.5 Jazz Pharmaceuticals Recent Development

11.12 CureVac

11.12.1 CureVac Company Details

11.12.2 CureVac Business Overview

11.12.3 CureVac Oligonucleotide Therapeutics Introduction

11.12.4 CureVac Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.12.5 CureVac Recent Development

11.13 Regulus Therapeutics

11.13.1 Regulus Therapeutics Company Details

11.13.2 Regulus Therapeutics Business Overview

11.13.3 Regulus Therapeutics Oligonucleotide Therapeutics Introduction

11.13.4 Regulus Therapeutics Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.13.5 Regulus Therapeutics Recent Development

11.14 ProQR

11.14.1 ProQR Company Details

11.14.2 ProQR Business Overview

11.14.3 ProQR Oligonucleotide Therapeutics Introduction

11.14.4 ProQR Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.14.5 ProQR Recent Development

11.15 Secarna

11.15.1 Secarna Company Details

11.15.2 Secarna Business Overview

11.15.3 Secarna Oligonucleotide Therapeutics Introduction

11.15.4 Secarna Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.15.5 Secarna Recent Development

11.16 MiNA Therapeutics

11.16.1 MiNA Therapeutics Company Details

11.16.2 MiNA Therapeutics Business Overview

11.16.3 MiNA Therapeutics Oligonucleotide Therapeutics Introduction

11.16.4 MiNA Therapeutics Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.16.5 MiNA Therapeutics Recent Development

11.17 Sylentis

11.17.1 Sylentis Company Details

11.17.2 Sylentis Business Overview

11.17.3 Sylentis Oligonucleotide Therapeutics Introduction

11.17.4 Sylentis Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.17.5 Sylentis Recent Development

11.18 Arrowhead

11.18.1 Arrowhead Company Details

11.18.2 Arrowhead Business Overview

11.18.3 Arrowhead Oligonucleotide Therapeutics Introduction

11.18.4 Arrowhead Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.18.5 Arrowhead Recent Development

11.19 Silence Therapeutics

11.19.1 Silence Therapeutics Company Details

11.19.2 Silence Therapeutics Business Overview

11.19.3 Silence Therapeutics Oligonucleotide Therapeutics Introduction

11.19.4 Silence Therapeutics Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.19.5 Silence Therapeutics Recent Development

11.20 Dicerna

11.20.1 Dicerna Company Details

11.20.2 Dicerna Business Overview

11.20.3 Dicerna Oligonucleotide Therapeutics Introduction

11.20.4 Dicerna Revenue in Oligonucleotide Therapeutics Business (2021–2026)

11.20.5 Dicerna Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Biogen

Sarepta Therapeutics

Jazz Pharmaceuticals

Ionis Pharmaceuticals

Alnylam

Nippon Shinyaku

SOBI

Novartis

BioNTech

Pfizer Inc

Moderna Therapeutics

CureVac

Regulus Therapeutics

ProQR

Secarna

Mina Therapeutics

Sylentis

Arrowhead

Silence Therapeutics

Dicerna

List of Tables

Table 1. Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Antisense Oligonucleotides (ASO)

Table 3. Key Players of siRNA

Table 4. Key Players of mRNA

Table 5. Global Oligonucleotide Therapeutics Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Oligonucleotide Therapeutics Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Oligonucleotide Therapeutics Market Size by Region (US$ Million), 2021–2026

Table 8. Global Oligonucleotide Therapeutics Market Share by Region (2021–2026)

Table 9. Global Oligonucleotide Therapeutics Forecasted Market Size by Region (US$ Million), 2027–2032

Table 10. Global Oligonucleotide Therapeutics Market Share by Region (2027–2032)

Table 11. Oligonucleotide Therapeutics Market Trends

Table 12. Oligonucleotide Therapeutics Market Drivers

Table 13. Oligonucleotide Therapeutics Market Challenges

Table 14. Oligonucleotide Therapeutics Market Restraints

Table 15. Global Oligonucleotide Therapeutics Revenue by Players (US$ Million), 2021–2026

Table 16. Global Oligonucleotide Therapeutics Market Share by Players (2021–2026)

Table 17. Global Top Oligonucleotide Therapeutics Players by Tier (Tier 1, Tier 2, and Tier 3), based on Oligonucleotide Therapeutics Revenue, 2025

Table 18. Ranking of Global Top Oligonucleotide Therapeutics Companies by Revenue (US$ Million) in 2025

Table 19. Global 5 Largest Players Market Share by Oligonucleotide Therapeutics Revenue (CR5 and HHI), 2021–2026

Table 20. Global Key Players of Oligonucleotide Therapeutics, Headquarters and Area Served

Table 21. Global Key Players of Oligonucleotide Therapeutics, Products and Applications

Table 22. Global Key Players of Oligonucleotide Therapeutics, Date of General Availability (GA)

Table 23. Mergers and Acquisitions, Expansion Plans

Table 24. Global Oligonucleotide Therapeutics Market Size by Type (US$ Million), 2021–2026

Table 25. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2021–2026)

Table 26. Global Oligonucleotide Therapeutics Forecasted Market Size by Type (US$ Million), 2027–2032

Table 27. Global Oligonucleotide Therapeutics Revenue Market Share by Type (2027–2032)

Table 28. Global Oligonucleotide Therapeutics Market Size by Application (US$ Million), 2021–2026

Table 29. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2021–2026)

Table 30. Global Oligonucleotide Therapeutics Forecasted Market Size by Application (US$ Million), 2027–2032

Table 31. Global Oligonucleotide Therapeutics Revenue Market Share by Application (2027–2032)

Table 32. North America Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 33. North America Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 34. North America Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 35. Europe Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. Europe Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 37. Europe Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 38. Asia-Pacific Oligonucleotide Therapeutics Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 39. Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (US$ Million), 2021–2026

Table 40. Asia-Pacific Oligonucleotide Therapeutics Market Size by Region (US$ Million), 2027–2032

Table 41. Latin America Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. Latin America Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 43. Latin America Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 44. Middle East & Africa Oligonucleotide Therapeutics Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2021–2026

Table 46. Middle East & Africa Oligonucleotide Therapeutics Market Size by Country (US$ Million), 2027–2032

Table 47. Sarepta Therapeutics Company Details

Table 48. Sarepta Therapeutics Business Overview

Table 49. Sarepta Therapeutics Oligonucleotide Therapeutics Product

Table 50. Sarepta Therapeutics Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 51. Sarepta Therapeutics Recent Development

Table 52. Ionis Pharmaceuticals Company Details

Table 53. Ionis Pharmaceuticals Business Overview

Table 54. Ionis Pharmaceuticals Oligonucleotide Therapeutics Product

Table 55. Ionis Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 56. Ionis Pharmaceuticals Recent Development

Table 57. Alnylam Company Details

Table 58. Alnylam Business Overview

Table 59. Alnylam Oligonucleotide Therapeutics Product

Table 60. Alnylam Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 61. Alnylam Recent Development

Table 62. Biogen Company Details

Table 63. Biogen Business Overview

Table 64. Biogen Oligonucleotide Therapeutics Product

Table 65. Biogen Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 66. Biogen Recent Development

Table 67. Nippon Shinyaku Company Details

Table 68. Nippon Shinyaku Business Overview

Table 69. Nippon Shinyaku Oligonucleotide Therapeutics Product

Table 70. Nippon Shinyaku Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 71. Nippon Shinyaku Recent Development

Table 72. Sobi Company Details

Table 73. Sobi Business Overview

Table 74. Sobi Oligonucleotide Therapeutics Product

Table 75. Sobi Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 76. Sobi Recent Development

Table 77. Novartis Company Details

Table 78. Novartis Business Overview

Table 79. Novartis Oligonucleotide Therapeutics Product

Table 80. Novartis Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 81. Novartis Recent Development

Table 82. BioNTech Company Details

Table 83. BioNTech Business Overview

Table 84. BioNTech Oligonucleotide Therapeutics Product

Table 85. BioNTech Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 86. BioNTech Recent Development

Table 87. Pfizer Company Details

Table 88. Pfizer Business Overview

Table 89. Pfizer Oligonucleotide Therapeutics Product

Table 90. Pfizer Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 91. Pfizer Recent Development

Table 92. Moderna Therapeutics Company Details

Table 93. Moderna Therapeutics Business Overview

Table 94. Moderna Therapeutics Oligonucleotide Therapeutics Product

Table 95. Moderna Therapeutics Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 96. Moderna Therapeutics Recent Development

Table 97. Jazz Pharmaceuticals Company Details

Table 98. Jazz Pharmaceuticals Business Overview

Table 99. Jazz Pharmaceuticals Oligonucleotide Therapeutics Product

Table 100. Jazz Pharmaceuticals Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 101. Jazz Pharmaceuticals Recent Development

Table 102. CureVac Company Details

Table 103. CureVac Business Overview

Table 104. CureVac Oligonucleotide Therapeutics Product

Table 105. CureVac Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 106. CureVac Recent Development

Table 107. Regulus Therapeutics Company Details

Table 108. Regulus Therapeutics Business Overview

Table 109. Regulus Therapeutics Oligonucleotide Therapeutics Product

Table 110. Regulus Therapeutics Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 111. Regulus Therapeutics Recent Development

Table 112. ProQR Company Details

Table 113. ProQR Business Overview

Table 114. ProQR Oligonucleotide Therapeutics Product

Table 115. ProQR Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 116. ProQR Recent Development

Table 117. Secarna Company Details

Table 118. Secarna Business Overview

Table 119. Secarna Oligonucleotide Therapeutics Product

Table 120. Secarna Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 121. Secarna Recent Development

Table 122. MiNA Therapeutics Company Details

Table 123. MiNA Therapeutics Business Overview

Table 124. MiNA Therapeutics Oligonucleotide Therapeutics Product

Table 125. MiNA Therapeutics Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 126. MiNA Therapeutics Recent Development

Table 127. Sylentis Company Details

Table 128. Sylentis Business Overview

Table 129. Sylentis Oligonucleotide Therapeutics Product

Table 130. Sylentis Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 131. Sylentis Recent Development

Table 132. Arrowhead Company Details

Table 133. Arrowhead Business Overview

Table 134. Arrowhead Oligonucleotide Therapeutics Product

Table 135. Arrowhead Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 136. Arrowhead Recent Development

Table 137. Silence Therapeutics Company Details

Table 138. Silence Therapeutics Business Overview

Table 139. Silence Therapeutics Oligonucleotide Therapeutics Product

Table 140. Silence Therapeutics Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 141. Silence Therapeutics Recent Development

Table 142. Dicerna Company Details

Table 143. Dicerna Business Overview

Table 144. Dicerna Oligonucleotide Therapeutics Product

Table 145. Dicerna Revenue in Oligonucleotide Therapeutics Business (US$ Million), 2021–2026

Table 146. Dicerna Recent Development

Table 147. Research Programs/Design for This Report

Table 148. Key Data Information from Secondary Sources

Table 149. Key Data Information from Primary Sources

Table 150. Authors List of This Report

List of Figures

Figure 1. Oligonucleotide Therapeutics Picture

Figure 2. Global Oligonucleotide Therapeutics Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Oligonucleotide Therapeutics Market Share by Type: 2025 vs 2032

Figure 4. Antisense Oligonucleotides (ASO) Features

Figure 5. siRNA Features

Figure 6. mRNA Features

Figure 7. Global Oligonucleotide Therapeutics Market Size by Application (US$ Million), 2021–2032

Figure 8. Global Oligonucleotide Therapeutics Market Share by Application: 2025 vs 2032

Figure 9. Neuromuscular Diseases Case Studies

Figure 10. hATTR Case Studies

Figure 11. COVID-19 Case Studies

Figure 12. Other Case Studies

Figure 13. Oligonucleotide Therapeutics Report Years Considered

Figure 14. Global Oligonucleotide Therapeutics Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 15. Global Oligonucleotide Therapeutics Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 16. Global Oligonucleotide Therapeutics Market Share by Region: 2025 vs 2032

Figure 17. Global Oligonucleotide Therapeutics Market Share by Players in 2025

Figure 18. Global Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 19. The Top 10 and 5 Players Market Share by Oligonucleotide Therapeutics Revenue in 2025

Figure 20. North America Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. North America Oligonucleotide Therapeutics Market Share by Country (2021–2032)

Figure 22. United States Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Canada Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Europe Oligonucleotide Therapeutics Market Share by Country (2021–2032)

Figure 26. Germany Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. France Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. U.K. Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Italy Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Russia Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Ireland Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Asia-Pacific Oligonucleotide Therapeutics Market Share by Region (2021–2032)

Figure 34. China Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Japan Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. South Korea Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Southeast Asia Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. India Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Australia & New Zealand Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Latin America Oligonucleotide Therapeutics Market Share by Country (2021–2032)

Figure 42. Mexico Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Brazil Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Middle East & Africa Oligonucleotide Therapeutics Market Share by Country (2021–2032)

Figure 46. Israel Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Saudi Arabia Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. UAE Oligonucleotide Therapeutics Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 50. Ionis Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 51. Alnylam Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 52. Biogen Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 53. Nippon Shinyaku Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 54. Sobi Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 55. Novartis Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 56. BioNTech Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 57. Pfizer Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 58. Moderna Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 59. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 60. CureVac Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 61. Regulus Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 62. ProQR Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 63. Secarna Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 64. MiNA Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 65. Sylentis Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 66. Arrowhead Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 67. Silence Therapeutics Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 68. Dicerna Revenue Growth Rate in Oligonucleotide Therapeutics Business (2021–2026)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Oligonucleotide Oligo Drugs Market Research Report 2024

Global Oligonucleotide based Therapy Medicinal Product Market Research Report 2024

Global Oligonucleotide Therapy based Drug Market Research Report 2024

Antisense and RNAi Therapeutics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Oligonucleotide Drug Delivery Market Research Report 2024

Global Peptide and Oligonucleotide Drugs Market Research Report 2024

Oligonucleotide Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oligonucleotide based Therapies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global CNS Specific Antisense Oligonucleotides Market Research Report 2024

Global Nucleic Acid Drugs Market Research Report 2025

Global Oligonucleotide Drugs ONs Market Research Report 2025

Global Antisense Oligonucleotides ASO Therapy Market Research Report 2024

Global Oligonucleotide Market Research Report 2025

Global Antisense Oligonucleotide Therapy for the Nervous System Market Research Report 2024

Global Antisense Oligonucleotides based Therapeutics Market Research Report 2024

Antisense and RNAi Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global RNA Interference RNAi Based Therapeutics Market Research Report 2024

Global RNAi Therapeutics Market Research Report 2024

Global RNA Therapeutics Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions